Bosnia and Herzegovina vs Finland: Tuberculosis treatment success rate
Bosnia and Herzegovina
37.0%
in 2023
Finland
34.0%
in 2023
Bosnia and Herzegovina rank
197th
Finland rank
199th
Tuberculosis treatment success rate over time
- Bosnia and Herzegovina
- Finland
How they compare
Bosnia and Herzegovina currently reports 37.0% against 34.0% in Finland, a difference of 3.0%.
That makes Bosnia and Herzegovina's figure about 1.1 times Finland's.
The two have swapped places 2 times across 17 shared years of data; in 2007 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 197th and Finland ranks 199th of 206 countries.
Bosnia and Herzegovina has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Finland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 95.0% | 40.7% | 54.3% | Bosnia and Herzegovina |
| 2010s | 63.9% | 39.1% | 24.8% | Bosnia and Herzegovina |
| 2020s | 45.2% | 16.8% | 28.5% | Bosnia and Herzegovina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis treatment success rate, Bosnia and Herzegovina or Finland?
- Bosnia and Herzegovina, at 37.0% against 34.0% in Finland as of 2023.
- What is the difference in tuberculosis treatment success rate between Bosnia and Herzegovina and Finland?
- 3.0%, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Finland?
- 17 years are reported by both, from 2007 to 2023.
- How do Bosnia and Herzegovina and Finland rank globally for tuberculosis treatment success rate?
- Bosnia and Herzegovina ranks 197th and Finland ranks 199th of 206 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Tuberculosis treatment success rate. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Treatment success rate among new and relapse cases.